- Home
- CIA vs OTLK Comparison
CIA vs OTLK Comparison
Compare CIA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIA | OTLK |
|---|---|---|
| Founded | 1969 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 249.6M |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CIA | OTLK |
|---|---|---|
| Price | $3.85 | $1.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 93.8K | ★ 13.4M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $255,616,000.00 | $8,146,123.00 |
| Revenue This Year | $3.10 | $1,430.98 |
| Revenue Next Year | $4.47 | $173.23 |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $4.40 | $0.16 |
| 52 Week High | $6.54 | $3.39 |
Technical Indicators
Market Signals| Indicator | CIA | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 28.86 | 41.12 |
| Support Level | $4.40 | $0.75 |
| Resistance Level | $5.63 | $1.83 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 13.59 | 18.48 |
Price Performance
Historical ComparisonAbout CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.